Latest Deals
Credit: Shutterstock/NicoElNino
Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech
The startup funding landscape for deep technology companies in healthcare is burgeoning and Zephyr AI is no exception. The US company closed a $111m Series A financing round to advance its artificial intelligence (AI) platform. Zephyr AI’s work focuses on curating large datasets that it combines with AI algorithms to build tools and products for the healthcare industry. The company is developing improved data federation tools and machine learning algorithms.
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Pi Health has launched on the clinical trial software-as-a-service (SaaS) market after completing a $30m Series A funding. The US company, created as a subsidiary of BeiGene three years ago, has developed a platform to help increase patient enrolment in cancer trials. The funding will enable Pi Health to operate as an independent company.
Alumis secures $259m to develop therapies for immune dysfunction
Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral therapies to address immune dysfunction. Life sciences investment company Foresite Capital and new investors Samsara BioCapital and venBio Partners jointly led the funding round. Additional participation came from other new investors, including SR One, Cormorant Asset Management and others.
Tierra raises $11.4 in Series A round for predictive AI protein maker
Tierra Biosciences has debuted on the pharma AI stage with the closing of an $11.4m Series A round for its protein engineering platform. The US-based company said that the funding will help advance and expand the reach of its platform that uses predictive AI to optimally manufacture proteins, according to a 12 March press release.
